Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old. (SHOview)

This study has been completed.
Information provided by (Responsible Party):
Ferring Pharmaceuticals Identifier:
First received: October 3, 2012
Last updated: July 16, 2014
Last verified: July 2014
Ovarian hyper stimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in IVF (In Vitro Fertilisation). The main objective of this study is to describe the incidence of moderate or severe forms of OHSS in women between 18 and 36 years of age treated with HP-hMG.

Condition Intervention
Ovarian Hyperstimulation Syndrome (OHSS)
Other: Highly purified menotropin (HP- hMG) treatment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.

Resource links provided by NLM:

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Incidence of moderate/severe OHSS [ Time Frame: 2-12 weeks ]

Secondary Outcome Measures:
  • Incidence of each form of OHSS: mild, moderate and severe [ Time Frame: 2-13 weeks ]
  • Incidence of moderate and of severe OHSS among patients treated by a GnRH agonist or antagonist desensitization protocol [ Time Frame: 2-13 weeks ]
  • OHSS clinical features description according to the Royal College of Obstetricians and Gynaecologists classification [ Time Frame: 2-13 weeks ]
  • Patients' baseline characteristics [ Time Frame: At baseline ]
  • Dosage adjustment, modification of the treatment, coasting and cycle cancellation, no hCG administration and embryo transfer cancellation [ Time Frame: Up to 3 weeks ]
  • Description and duration of hospitalisation, treatments prescribed [ Time Frame: 2-13 weeks ]
  • Frequency and reasons for stimulation arrest and no embryo transfer decision [ Time Frame: 2-4 weeks ]
  • Number of oocytes retrieved, number of mature oocytes, fertilization rate, embryo quality, embryo freezing, number and quality of transferred embryos [ Time Frame: 2-3 weeks ]
  • Description of serious and not serious adverse events [ Time Frame: 2-13 weeks ]
  • Description of patient's compliance to the prescribed treatment [ Time Frame: 2-4 weeks ]
  • Clinical pregnancy rate, spontaneous miscarriage and ongoing pregnancy rate [ Time Frame: 4-13 weeks ]

Biospecimen Retention:   None Retained
No biological samples

Enrollment: 455
Study Start Date: November 2012
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Highly purified menotropin (HP-hMG) treatment
Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
Other: Highly purified menotropin (HP- hMG) treatment
No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice


Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.

Inclusion Criteria:

  • Women who present infertility of more than one year and are candidates for a first or second IVF cycle with or without ICSI for whom HP-hMG is prescribed for COS.
  • Absence of infertility treatment during the last 3 months before enrolment.
  • Age: from 18 to 36 years old.
  • BMI between 18 and 30 kg / m².
  • Presence of both ovaries accessible to puncture and absence of ovarian or uterine abnormalities.
  • Male or female infertility.
  • Ovarian stimulation by HP-hMG with pituitary desensitization by a GnRH agonist or antagonist.
  • Normal ovarian reserve according to physician habitual evaluation.
  • Consent to participate of the no-interventional study and signature of the patients' information sheet.

Exclusion Criteria:

  • Presence of a chronic disease, cancer or endocrine disease that could potentially influence the results of the stimulation or that represents a contraindication for ovarian stimulation.
  • Known endometriosis grade III or IV.
  • Contraindication to the use of gonadotropins or current pregnancy diagnosed by the clinician.
  • Recurrent miscarriages, known genetic disease of one of the partners or indication of a preimplantation genetic diagnosis (PGD).
  • Smoking over than 10 cigarettes / day.´
  • Participation in an interventional study at the time of inclusion.
  • Known poor ovarian response in a previous cycle of stimulation (number of oocyte collected ≤ 3, and / or more than 2 previous IVF/ICSI cycles and / or abnormal result in ovarian reserve test (AMH < 1 ng/ml with Immunotech equipment or AMH<0.7 ng/ml with DSL equipment).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01703728

Cabinet Mirabeau Roy René (there may be other sites in this country)
Aix En Provence, France
Hôtel Dieu
Angers, France
Clinique La Chataigneraie
Beaumont, France
CHU Pellegrin
Bordeaux, France
Clinique Léonard de Vinci
Chambray les tours, France
Créteil, France
Hôpital Victor Jousselin
Dreux, France
Institut Rhonalpin
Ecully, France
Cabinet Médical Maréchal Leclerc
Grenoble, France
Groupe Hospitalier du Havre - Hôpital Jacques Monod
Le Havre, France
Cabinet Médical Lille avenue de Dunkerque
Lille, France
Hôpital Jeanne de Flandre
Lille, France
Hôpital Privé Natecia
Lyon, France
CHU de Marseille -Hôpital Conception
Marseille, France
Hôpital Maternité de Metz
Metz, France
CHU de Nantes
Nantes, France
Cabinet Médical de Prony
Paris, France
Hôpital St Vincent de Paul
Paris, France
CHU de Rennes
Rennes, France
Clinique Mutualiste La Sagesse
Rennes, France
Sponsors and Collaborators
Ferring Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals Identifier: NCT01703728     History of Changes
Other Study ID Numbers: 000012
Study First Received: October 3, 2012
Last Updated: July 16, 2014

Additional relevant MeSH terms:
Ovarian Hyperstimulation Syndrome
Pathologic Processes
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases processed this record on May 25, 2017